Stocks to Watch, 29 July: Stocks like IndusInd Bank, Waaree Energies, NTPC Green Energy, KEC International, Torrent Pharma, PNC Infratech, RPSG Ventures, Monarch Surveyors, Paradeep Phosphates, and Mazagon Dock Shipbuilders will be in focus on July 29.
Consolidation is expected to continue in the upcoming sessions, with resistance and support at last week's high-low. Below are some short-term trading ideas to consider.
Stocks to watch, 12, June: Stocks like Cyient, ICICI Bank, Maruti Suzuki India, Canara Bank, Kellton Tech Solutions, GMM Pfaudler, Titagarh Rail Systems, Zydus Lifesciences, CE Info Systems Nazara Technologies, Sterlite Technologies, HG Infra Engineering, Hindustan Copper, and Angel One will be in focus on June 12.
rbiMed Asia IV Mauritius FVCI Ltd has launched a Rs 256.8 crore stake sale, representing 2.27 percent of the company’s equity, at Rs 249.95 per share.
Stocks to Watch, 20 May: Stocks like CMS Info Systems, GMR Power and Urban Infra, New India Assurance Company, Marksans Pharma, Ami Organics, Bharat Bijlee, Le Travenues Technology, Mangalam Organics, Integrity Infrabuild Developers, Power Grid Corporation of India, Bharat Electronics, DLF, ACME Solar Holdings, Borosil, Petronet LNG, and DOMS Industries will be in focus on May 20.
The benchmark indices are expected to consolidate in the upcoming sessions and look for fresh triggers. Below are some trading ideas for the near term.
Marksans Pharma delivered double-digit revenue as well as net profit growth in April-June along with an expansion in its operating margins.
Marksans Pharma received the UK health regulator's nod to market its new oral solution for epilepsy patients.
MIT's recent investment in Marksans Pharma underscores the small-cap's hidden gem status, fuelled by its strong presence in stable OTC markets and strategic growth initiatives, signalling promising prospects for revenue and profit expansion.
The US Food and Drug Administration (USFDA) had conducted a routine current Good Manufacturing Practices (cGMP) inspection at the manufacturing facility from April 9-17, 2024, the company said in a regulatory filing.
Gguaifenesin helps loosen phlegm and thin bronchial secretions to rid the bronchial passageways of mucus, the company has said